CureVac N.V. (NASDAQ:CVAC) Given Average Rating of “Hold” by Analysts

Shares of CureVac N.V. (NASDAQ:CVAC) have been assigned a consensus rating of “Hold” from the six analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.8333.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CureVac in a research note on Tuesday, December 16th.

CureVac Price Performance

CureVac stock opened at $4.66 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.69 and a current ratio of 3.70. CureVac has a 52 week low of $4.00 and a 52 week high of $4.68. The stock has a market capitalization of $1.05 billion, a P/E ratio of 6.47 and a beta of 1.77. The stock has a fifty day moving average of $4.71 and a 200-day moving average of $5.14.

CureVac (NASDAQ:CVAC) last issued its earnings results on Monday, November 24th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.07. The firm had revenue of $63.53 million during the quarter, compared to the consensus estimate of $21.40 million. CureVac had a negative return on equity of 23.03% and a net margin of 199.92%. On average, sell-side analysts expect that CureVac will post 0.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CureVac

A number of hedge funds and other institutional investors have recently modified their holdings of CVAC. Caitong International Asset Management Co. Ltd grew its holdings in CureVac by 354.8% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock worth $30,000 after purchasing an additional 4,375 shares during the period. Headlands Technologies LLC purchased a new position in CureVac during the second quarter valued at $35,000. L2 Asset Management LLC bought a new stake in CureVac in the second quarter worth $70,000. Integrated Wealth Concepts LLC increased its holdings in shares of CureVac by 25.0% during the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after acquiring an additional 3,000 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of CureVac in the 4th quarter worth about $79,000. 17.26% of the stock is currently owned by hedge funds and other institutional investors.

CureVac Company Profile

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.